Repurposed Drugs, Targeted Therapy, Cancer Metabolism, Akkermansia and Immunotherapy: A 2026 Evidence Review
Cancer treatment is increasingly moving from a one-size-fits-all model toward biologically stratified combination therapy. Modern oncology can now target specific molecular alterations, activate antitumor immunity, manipulate cellular metabolism and, potentially, modify the gut microbiome.
This review integrates four related areas of research: targeted therapy, immunotherapy, metabolic oncology and drug repurposing, with particular attention to the emerging role of Akkermansia and the gut microbiome.
Targeted therapies provide the clearest example of precision oncology. In EGFR-mutated non-small-cell lung cancer (NSCLC), osimertinib (Tagrisso) is an established EGFR tyrosine-kinase inhibitor for appropriately selected patients. FDA labeling includes first-line treatment of metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations, among other approved settings.
Immunotherapies, including PD-1/PD-L1 and CTLA-4 checkpoint inhibitors and CAR-T-cell therapy, have produced durable responses in selected cancers, but resistance remains common. Tumor genetics, antigenicity, the tumor microenvironment, metabolic conditions and host immune biology all contribute to response and resistance.
The gut microbiome has emerged as another potentially important determinant. Akkermansia muciniphila has been associated with response to immune checkpoint blockade in several studies, while newer research has extended the microbiome hypothesis to CAR-T therapy. A 2025 study reported loss of Akkermansia species in patients with B-cell lymphoma receiving CD19 CAR-T therapy and found that Akkermansia massiliensis supplementation enhanced CAR-T activity in experimental models.
Drug repurposing adds another experimental layer. Agents such as metformin, statins, aspirin, ivermectin, mebendazole and fenbendazole have been investigated for potential anticancer or immunomodulatory effects. However, the strength of evidence varies considerably, and most remain investigational as cancer therapies.
The August 2026 case series describing ivermectin and fenbendazole alongside Tagrisso in stage IV EGFR-mutated NSCLC illustrates a clinically interesting hypothesis: whether experimental repurposed drugs can add benefit to an established targeted therapy. Such a case can generate a research hypothesis, but cannot establish that the additional drugs caused the response or improve outcomes over targeted therapy alone.
Overall, the most scientifically defensible model is not "repurposed drugs versus conventional oncology." It is a layered precision-oncology framework in which molecularly matched targeted therapy and established immunotherapy remain the evidence-based foundation, while metabolic, microbiome and repurposed-drug strategies are evaluated as potential experimental modifiers.
The future of oncology may involve combining information from the tumor genome, immune system, tumor microenvironment, metabolism and microbiome. However, biological plausibility is not clinical proof. Experimental combinations should be evaluated in properly designed clinical trials rather than adopted as unvalidated treatment protocols.
- Introduction
- The New Oncology Framework
- Targeted Therapy
- EGFR-Mutated NSCLC and Tagrisso
- The Ivermectin + Fenbendazole + Tagrisso Case
- Targeted Therapy Resistance
- Immunotherapy
- Why Immunotherapy Fails
- Tumor Microenvironment
- Cancer Metabolism and Immune Function
- The Gut Microbiome and Immunotherapy
- Akkermansia and Cancer Immunotherapy
- FMT and Microbiome Manipulation
- Akkermansia and CAR-T Therapy
- Diet, Fiber and the Microbiome
- Cancer Drug Repurposing
- Metformin
- Statins
- Aspirin
- Ivermectin
- Mebendazole
- Fenbendazole
- Methylene Blue and Mitochondrial Biology
- Combination Oncology
- AI and Systems Biology
- Evidence Hierarchy
- What Clinical Trials Need to Demonstrate
- Safety and Clinical Limitations
- Future Directions
- Conclusion
- Frequently Asked Questions
- References
1. Introduction
Cancer therapy has entered an era in which treatment increasingly depends on the biological characteristics of an individual tumor.
The traditional model was relatively simple: surgery, radiation, chemotherapy and, more recently, immunotherapy. Modern precision oncology is considerably more complex.
A patient's treatment may now depend on:
- Specific oncogenic mutations.
- Gene fusions.
- Protein-expression biomarkers.
- DNA repair defects.
- Tumor mutation burden.
- Microsatellite instability.
- Immune-cell infiltration.
- Tumor metabolism.
- Mechanisms of acquired drug resistance.
- Host factors and, increasingly, the gut microbiome.
At the same time, hundreds of existing drugs are being investigated for possible anticancer applications.
This has created enormous interest in combining established oncology therapies with repurposed drugs, metabolic interventions and microbiome-modulating strategies.
But there is a critical distinction:
An FDA-approved targeted therapy supported by randomized clinical trials should not be placed in the same evidence category as a repurposed drug supported primarily by cell culture, animal experiments or case reports.
2. The New Oncology Framework
The emerging model can be summarized as five interconnected biological layers.
Layer 1 — Molecular tumor biology
What genetic alteration is driving the cancer?
Layer 2 — Targeted therapy
Is there an established drug that directly inhibits that molecular driver?
Layer 3 — Immune biology
Can the immune system recognize and destroy the cancer?
Layer 4 — Metabolism and tumor microenvironment
Does the metabolic environment support or suppress tumor-cell killing?
Layer 5 — Microbiome and host biology
Does the gut ecosystem influence systemic immunity or treatment response?
Repurposed drugs can potentially interact with several of these layers, but their position in the hierarchy depends on clinical evidence.
3. Targeted Therapy
Targeted therapy is one of the clearest successes of precision oncology.
Unlike conventional chemotherapy, which generally affects rapidly dividing cells, targeted agents are designed to interfere with specific molecular abnormalities that drive tumor growth or survival.
Examples include therapies directed against:
- EGFR
- ALK
- ROS1
- BRAF
- KRAS G12C
- HER2
- RET
- MET
- NTRK
- FGFR
- PI3K and related signaling pathways
The exact treatment depends on the cancer type, mutation and clinical setting.
This is important because targeted therapy is not simply another "drug option." It is often selected because a molecular vulnerability has been demonstrated to matter to the tumor.
When a tumor contains a validated actionable driver and an effective targeted therapy exists, that therapy should form the evidence-based foundation of treatment.
4. EGFR-Mutated NSCLC and Tagrisso
EGFR-mutated NSCLC provides a particularly useful example of precision oncology.
Osimertinib, marketed as Tagrisso, is an EGFR tyrosine-kinase inhibitor.
FDA labeling includes first-line treatment of adults with metastatic NSCLC whose tumors harbor EGFR exon 19 deletions or exon 21 L858R mutations detected by an appropriate FDA-approved test. The drug also has other approved NSCLC indications and combinations. :contentReference[oaicite:3]{index=3}
This means that the biological rationale for osimertinib is substantially different from the rationale for an experimental repurposed drug.
The targeted therapy is selected because the tumor contains an actionable EGFR alteration.
The central clinical challenge then becomes:
That question creates the potential research space for combination strategies.
5. The Ivermectin + Fenbendazole + Tagrisso Case Series
The August 2026 case reports describing ivermectin and fenbendazole in conjunction with Tagrisso in stage IV NSCLC provides an interesting case-study framework.
The scientifically relevant question is not whether a patient receiving several agents experienced a response.
The more rigorous question is whether the experimental agents provide an incremental benefit beyond the established targeted therapy.
Could a repurposed drug modify tumor-cell signaling, metabolism, stress responses or the tumor microenvironment in a manner that increases sensitivity to an established targeted therapy?
This is a legitimate research question.
It is not, however, evidence that ivermectin or fenbendazole improves the efficacy of osimertinib.
If a patient with EGFR-mutated NSCLC responds while receiving osimertinib, ivermectin and fenbendazole, several explanations remain possible:
- The response may be entirely attributable to osimertinib.
- The repurposed drugs may contribute nothing.
- One or both repurposed drugs may contribute an effect.
- The drugs could interact biologically.
- The response could reflect individual tumor biology.
A controlled comparative trial is required to distinguish these possibilities.
This is the correct way to use an individual case scientifically: as a hypothesis generator, not as proof of efficacy.
6. Targeted Therapy Resistance
The rationale for studying combinations becomes stronger when resistance develops.
Cancer is evolutionarily dynamic. Treatment creates selective pressure, and surviving tumor populations can acquire or select for mechanisms that allow continued growth.
Resistance to EGFR-targeted therapy may involve:
- Secondary EGFR alterations.
- MET amplification.
- Alternative signaling pathways.
- Histologic transformation.
- Changes in tumor-cell state.
- Other genomic or non-genomic mechanisms.
Therefore, simply adding an unrelated drug after progression may not be rational.
The preferred precision-oncology approach is to determine why the tumor became resistant.
Molecular reassessment
Repeat tissue biopsy or circulating tumor DNA testing can sometimes identify new molecular alterations and guide subsequent therapy.
This creates a crucial distinction:
7. Immunotherapy
Immune checkpoint inhibitors have transformed treatment for numerous cancers.
Major targets include:
- PD-1
- PD-L1
- CTLA-4
- LAG-3 and other emerging immune checkpoints
These therapies do not primarily work by directly poisoning cancer cells.
Instead, they modify inhibitory signals that regulate T-cell activity.
This creates an important biological requirement: the patient must have an immune system capable of generating an effective antitumor response.
8. Why Immunotherapy Fails
Checkpoint blockade can fail for many reasons.
- The tumor may have low antigenicity.
- Antigen presentation may be impaired.
- T cells may fail to infiltrate the tumor.
- The tumor may be immunologically "cold."
- Suppressive myeloid populations may dominate.
- Regulatory T cells may suppress immunity.
- Metabolic conditions may impair T-cell function.
- The tumor may evolve immune escape mechanisms.
- The microbiome may influence systemic immune activity.
This explains why simply increasing the dose of an immune checkpoint inhibitor is not necessarily the solution.
The limiting factor may lie somewhere else in the biological system.
9. Tumor Microenvironment
The tumor microenvironment (TME) contains cancer cells together with immune cells, fibroblasts, blood vessels, extracellular matrix and signaling molecules.
This environment can either support or suppress antitumor immunity.
Important components include:
- CD8+ cytotoxic T cells.
- Regulatory T cells.
- Dendritic cells.
- Tumor-associated macrophages.
- Myeloid-derived suppressor cells.
- Cancer-associated fibroblasts.
- Endothelial cells.
- Extracellular matrix.
- Hypoxic regions.
- Metabolic gradients.
The TME is therefore a potential bridge between targeted therapy, metabolism and immunotherapy.
10. Cancer Metabolism and Immune Function
Cancer cells frequently alter glucose, amino-acid and lipid metabolism.
These changes can influence the local environment in which immune cells operate.
Glucose competition
Activated T cells require substantial metabolic resources. Highly glycolytic tumor cells may compete for nutrients.
Lactate
Tumor-associated lactate accumulation can contribute to an acidic microenvironment and may affect immune-cell function.
Hypoxia
Low oxygen availability can alter tumor metabolism, angiogenesis and immune-cell behavior.
Mitochondrial function
T-cell persistence and function depend on mitochondrial fitness and metabolic flexibility.
"Starving cancer" is not a scientifically adequate description of metabolic oncology. Tumor cells and immune cells share many metabolic requirements. An intervention that suppresses one metabolic pathway can potentially affect both.
11. The Gut Microbiome and Immunotherapy
The gut microbiome has become an important area of cancer-immunotherapy research.
The microbiome can influence:
- Intestinal barrier function.
- Dendritic-cell activity.
- T-cell priming.
- Systemic inflammatory signaling.
- Microbial metabolite production.
- Immune-cell differentiation.
- Response to immune checkpoint blockade.
Research has identified associations between particular microbial communities and response to checkpoint inhibitors.
However, microbiome science is moving beyond the simplistic idea of identifying one "good" bacterium.
The clinically relevant unit may ultimately be the functional microbiome—the combined microbial community and the metabolites it produces.
12. Akkermansia and Cancer Immunotherapy
Akkermansia muciniphila is one of the best-known bacteria in the immunotherapy-microbiome literature.
The original landmark research by Routy and colleagues linked the gut microbiome, antibiotic exposure and response to PD-1 blockade. Subsequent research has continued to investigate Akkermansia and related microbial communities.
More recent clinical research has reported associations between tumor or gut Akkermansia and response to immune checkpoint inhibitors, including in NSCLC. :contentReference[oaicite:4]{index=4}
A biomarker can be associated with response without being sufficiently validated to predict an individual patient's outcome.
Therefore, Akkermansia should currently be described as an emerging biomarker and therapeutic research target, rather than a clinically validated stand-alone predictor.
12.1 Mechanistic evidence
The evidence is particularly interesting because experimental models suggest that Akkermansia can influence immune responses rather than merely correlate with them.
Recent research has also reported that Akkermansia muciniphila can enhance anti-PD-1 activity in experimental gastric cancer models by remodeling the tumor immune microenvironment. :contentReference[oaicite:5]{index=5}
Other experimental work has investigated engineered Akkermansia-derived vesicles as potential immunotherapy-enhancing platforms. :contentReference[oaicite:6]{index=6}
These studies are scientifically exciting but remain preclinical.
13. FMT and Microbiome Manipulation
One of the strongest demonstrations that the microbiome may influence immunotherapy comes from fecal microbiota transplantation (FMT).
Early clinical studies in melanoma investigated FMT from patients who had responded to PD-1 blockade and then administered renewed anti-PD-1 treatment to patients whose tumors had previously been resistant.
Responses occurred in subsets of patients.
These findings are important because they move the field beyond simple correlation.
Nevertheless, FMT is not established as a routine treatment for immunotherapy resistance.
14. Akkermansia and CAR-T Therapy
The microbiome hypothesis has now expanded beyond immune checkpoint inhibitors.
A 2025 Cancer Discovery study examined the relationship between gut microbiota and CD19 CAR-T therapy in B-cell lymphoma. The investigators reported profound intestinal dysbiosis following CAR-T infusion, including loss of Akkermansia species, and found an association with treatment resistance. :contentReference[oaicite:7]{index=7}
In experimental models, oral Akkermansia massiliensis supplementation increased CAR-T-cell infiltration, promoted a CD8+ Tc1 phenotype and increased tryptophan-derived indole metabolites, improving tumor control.
The investigators also found that the effect depended on the aryl hydrocarbon receptor pathway.
This is a compelling translational finding, but it does not establish that commercially available Akkermansia products improve CAR-T outcomes in humans.
15. Diet, Fiber and the Microbiome
Diet is one of the most powerful environmental influences on the gut microbiome.
Fiber, plant diversity and dietary composition can affect microbial abundance and metabolite production.
However, there is a major difference between:
"This dietary pattern supports a healthier microbiome"
and:
"This dietary pattern treats cancer or makes immunotherapy work."
The first statement may be supported by substantial health research. The second requires direct clinical evidence.
Patients receiving cancer therapy should therefore avoid extreme dietary interventions based solely on microbiome theories.
16. Cancer Drug Repurposing
Drug repurposing investigates whether an existing medication can be used for a new disease.
Cancer repurposing is attractive because existing drugs may already have:
- Known pharmacology.
- Manufacturing infrastructure.
- Human safety data.
- Established dosing experience.
- Known drug-interaction profiles.
But these advantages do not eliminate the need for cancer-specific clinical trials.
An established antiparasitic dose, for example, does not automatically establish an appropriate oncology dose.
17. Metformin
Metformin has attracted extensive cancer-repurposing research because of its effects on glucose metabolism, insulin signaling and AMPK-related pathways.
Observational studies have generated substantial interest.
However, observational associations can be distorted by differences between patients who take metformin and those who do not.
Randomized clinical evidence has not established metformin as a universal anticancer therapy.
Metformin remains a legitimate research candidate, not a proven general-purpose cancer treatment or immunotherapy enhancer.
18. Statins
Statins inhibit HMG-CoA reductase and alter the mevalonate pathway.
Because this pathway is involved in lipid metabolism, membrane biology and intracellular signaling, statins have been investigated for potential anticancer effects.
Observational studies are interesting, but randomized evidence is necessary before statins can be considered anticancer therapy.
19. Aspirin
Aspirin affects cyclooxygenase signaling, platelet biology and inflammation.
Its potential role in cancer prevention, particularly colorectal cancer, has been extensively studied.
However, aspirin can cause significant bleeding.
Therefore, cancer-related hypotheses must always be balanced against established risks and indications.
20. Ivermectin
Ivermectin is one of the most widely discussed repurposed drugs in cancer research.
Laboratory studies have identified multiple possible anticancer mechanisms, including effects on signaling pathways, cellular stress and transport processes.
This has generated interest in combining ivermectin with established anticancer therapies.
However, laboratory activity does not establish clinical efficacy.
Clinical trials are therefore substantially more important than mechanistic speculation.
Ivermectin is not an established cancer treatment or validated immunotherapy enhancer. It should not be substituted for evidence-based oncology treatment.
21. Mebendazole
Mebendazole is an antiparasitic drug that has been investigated in cancer models because of effects involving microtubules and other cellular pathways.
The preclinical rationale is interesting.
Human clinical evidence, however, remains insufficient to establish mebendazole as a standard cancer therapy.
The distinction between laboratory activity and patient benefit is especially important for repurposed drugs because the concentrations producing effects in experimental systems may not be achievable safely in humans.
22. Fenbendazole
Fenbendazole has attracted extensive public interest after reports of cancer responses in individual patients.
Laboratory research has suggested possible effects on microtubules, oxidative stress and cellular metabolism.
However, human clinical evidence remains extremely limited.
Fenbendazole should currently be considered an experimental cancer-repurposing hypothesis, not an established anticancer drug.
Case reports cannot determine whether a response was caused by fenbendazole, conventional therapy, spontaneous variation in disease course or another factor.
23. Methylene Blue and Mitochondrial Biology
Methylene blue has attracted interest because of its redox and mitochondrial effects.
The hypothesis is relevant to metabolic oncology because mitochondrial function influences both tumor biology and immune-cell function.
However, there is currently insufficient clinical evidence to support methylene blue as routine cancer therapy.
24. Combination Oncology: The Correct Hierarchy
The strongest version of the combination-therapy hypothesis is not "add as many potentially anticancer drugs as possible."
A scientifically defensible framework is:
1. Identify the molecular driver.
2. Use the validated targeted therapy when one exists.
3. Characterize resistance mechanisms.
4. Determine whether immune biology contributes to response or resistance.
5. Characterize metabolic vulnerabilities.
6. Investigate microbiome effects where biologically justified.
7. Test repurposed drugs only when a specific mechanistic hypothesis exists.
8. Validate the combination prospectively.
This approach is fundamentally different from uncontrolled polypharmacy.
25. AI and Systems Biology
The increasing complexity of cancer biology creates a natural role for artificial intelligence.
AI systems can potentially integrate:
- Whole-genome sequencing.
- Transcriptomics.
- Proteomics.
- Metabolomics.
- Immune-cell profiles.
- PD-L1 expression.
- TMB.
- MSI status.
- ctDNA.
- Microbiome composition.
- Microbial metabolites.
- Medication history.
- Longitudinal clinical outcomes.
The goal would be to identify treatment combinations that would otherwise be difficult to discover.
For example, AI could theoretically identify a subgroup of EGFR-mutated tumors that develops a particular metabolic phenotype after EGFR inhibition and then nominate a metabolic intervention for prospective testing.
A computationally predicted synergy is a hypothesis. It is not evidence that the combination improves survival.
26. Evidence Hierarchy
| Evidence level | Typical evidence | What it can tell us |
|---|---|---|
| 1 | Mechanistic hypothesis | Whether a biological idea is plausible |
| 2 | Cell culture | Whether an intervention affects cancer cells under experimental conditions |
| 3 | Animal models | Whether an intervention has in-vivo activity in a model system |
| 4 | Case reports | Whether an unusual clinical observation deserves investigation |
| 5 | Observational cohorts | Whether an association exists in real-world patients |
| 6 | Phase I/II trials | Safety, dosing and preliminary activity |
| 7 | Randomized controlled trials | Causal evidence of comparative benefit |
| 8 | Multiple confirmatory trials | Strong evidence suitable for broad clinical adoption |
- Osimertinib for appropriately selected EGFR-mutated NSCLC: established targeted therapy.
- Checkpoint inhibitors: established therapies for numerous biomarker-defined cancers.
- CAR-T: established cellular therapy for selected malignancies.
- Akkermansia: promising biomarker and experimental therapeutic target.
- FMT for immunotherapy resistance: promising early clinical research.
- Metformin: extensive research but not established as general cancer treatment.
- Ivermectin: investigational repurposing strategy.
- Mebendazole: investigational.
- Fenbendazole: highly experimental.
27. What Clinical Trials Need to Demonstrate
A combination strategy should not be considered successful merely because tumor shrinkage occurs.
A rigorous trial should evaluate:
- Overall survival.
- Progression-free survival.
- Objective response rate.
- Duration of response.
- Quality of life.
- Treatment-related toxicity.
- Biomarker-defined subgroups.
- Mechanisms of resistance.
For microbiome studies, additional measurements should include:
- Baseline microbiome composition.
- Longitudinal microbiome changes.
- Microbial functional pathways.
- Microbial metabolites.
- Antibiotic exposure.
- Diet.
- Probiotic use.
For targeted therapy studies, molecular monitoring should ideally establish whether the experimental intervention changes the biology of resistance.
28. Safety and Clinical Limitations
Combination therapy creates a fundamental problem: every additional intervention introduces another opportunity for toxicity, drug interactions and confounding.
This is especially important in patients with advanced cancer who may already receive multiple medications.
Potential problems include:
- Drug-drug interactions.
- Liver toxicity.
- Kidney toxicity.
- Cardiac effects.
- Bleeding risk.
- Immune-related adverse events.
- Altered drug metabolism.
- Microbiome disruption.
- Unexpected effects on immune function.
For example, Tagrisso has important safety considerations including interstitial lung disease/pneumonitis, QTc prolongation and cardiomyopathy in its prescribing information.
Therefore, adding experimental drugs to an established targeted therapy should not be treated as biologically neutral.
The existence of a plausible pathway does not establish that manipulating it in a patient is beneficial—or safe.
29. Future Directions
29.1 Molecularly guided combinations
Future trials will increasingly select patients according to specific resistance mechanisms rather than cancer type alone.
29.2 Microbiome biomarkers
Microbiome characteristics may eventually complement PD-L1, TMB, MSI and other biomarkers.
29.3 Precision microbiome therapeutics
The field is moving toward defined microbial consortia, engineered bacteria, microbial metabolites and other precisely controlled interventions.
29.4 Microbiome + CAR-T
The Akkermansia/CAR-T findings provide an intriguing new research direction. :contentReference[oaicite:9]{index=9}
29.5 Targeted therapy + metabolism
A major research question is whether metabolic vulnerabilities that emerge during targeted therapy can be exploited therapeutically.
29.6 Targeted therapy + repurposed drugs
The EGFR/Tagrisso example illustrates a broader hypothesis: repurposed drugs could potentially modify resistance biology or tumor-cell stress.
This should be tested in controlled trials rather than inferred from individual cases.
29.7 AI-guided precision oncology
AI may eventually integrate genomic, immune, metabolic and microbiome information to identify patient-specific combinations.
30. Conclusion
The most important development in modern oncology may not be the discovery of one universal anticancer drug.
It is the ability to understand cancer as a complex biological system.
The emerging model involves:
↓
Targeted therapy
↓
Resistance biology
↓
Tumor microenvironment
↓
Immune response
↓
Metabolism
↓
Microbiome
↓
Rational experimental combinations
↓
Prospective clinical validation
The integration of the three OneDayMD/AestheticsAdvisor articles provides a useful illustration of this evolution.
The original repurposed-drug framework asks whether established medicines can affect cancer biology.
The January 2026 work extends the question to combinations with modern immunotherapies and cellular therapies.
The March 2026 Akkermansia analysis adds the microbiome as another determinant of immune response.
The May 2026 EGFR/Tagrisso case series adds a critical precision-oncology layer: repurposed drugs should be studied in the context of established molecularly targeted therapy, not as replacements for it.
This distinction is essential.
For a patient with an actionable EGFR mutation, an evidence-based EGFR-targeted therapy such as osimertinib occupies a completely different evidentiary category from ivermectin or fenbendazole.
Likewise, an observed association between Akkermansia and immunotherapy response does not mean that simply taking an Akkermansia supplement will reproduce that response.
And a computational prediction of drug synergy does not establish clinical benefit.
The most promising future of cancer therapy is likely to be precision combination oncology: selecting treatments according to molecular drivers, resistance mechanisms, immune phenotype, metabolic state and potentially microbiome characteristics.
But precision does not mean adding more treatments.
It means selecting the right treatment for the right biological vulnerability at the right time—and demonstrating that the combination improves meaningful patient outcomes in well-designed clinical trials.
31. Frequently Asked Questions
What is the difference between targeted therapy and drug repurposing?
Targeted therapy is designed or selected to inhibit a specific molecular vulnerability in cancer. Drug repurposing investigates whether an existing medicine developed for another indication may have useful anticancer effects.
Is Tagrisso a targeted therapy?
Yes. Tagrisso (osimertinib) is an EGFR tyrosine-kinase inhibitor used for appropriately selected EGFR-mutated NSCLC and other approved NSCLC settings. :contentReference[oaicite:11]{index=11}
Is ivermectin a targeted cancer therapy?
No. Ivermectin is an established antiparasitic drug being investigated for potential anticancer effects. Its use as a cancer treatment remains investigational.
Is fenbendazole an established cancer treatment?
No. Fenbendazole remains an experimental cancer-repurposing hypothesis supported primarily by preclinical evidence and anecdotal reports rather than definitive clinical trials.
Can ivermectin and fenbendazole be combined with Tagrisso?
The combination has been described in individual patient reports, but this does not establish that it is effective or safe as a cancer treatment. Any such combination should be considered experimental and evaluated with appropriate medical supervision and, ideally, within clinical research.
Does Akkermansia improve immunotherapy?
Experimental and observational evidence suggests that Akkermansia may influence immune checkpoint therapy. However, targeted Akkermansia treatment has not been established as standard cancer therapy.
Can Akkermansia improve CAR-T therapy?
Preclinical research suggests that Akkermansia can enhance CAR-T activity through immune and microbial-metabolite pathways. A 2025 study reported increased CAR-T potency following Akkermansia supplementation in experimental models, but clinical efficacy in routine patients remains unproven. :contentReference[oaicite:12]{index=12}
Can antibiotics reduce immunotherapy effectiveness?
Observational studies have associated antibiotic exposure around immune checkpoint treatment with poorer outcomes, potentially because of microbiome disruption. However, patients should not avoid medically necessary antibiotics.
Can FMT overcome immunotherapy resistance?
Early clinical studies suggest that FMT from immunotherapy responders may restore responses in a subset of previously resistant patients. The strategy remains investigational.
Can metabolism affect immunotherapy?
Yes. Tumor glucose consumption, lactate accumulation, hypoxia, amino-acid availability and mitochondrial biology can influence immune-cell function. Translating these mechanisms into effective treatments remains an active area of research.
Can AI identify the best cancer combination?
AI can identify candidate combinations and biological relationships, but predictions require laboratory and clinical validation. AI cannot replace randomized clinical trials.
32. References
- U.S. Food and Drug Administration. TAGRISSO (osimertinib) Prescribing Information. FDA.
- U.S. Food and Drug Administration. Oncology/Cancer/Hematologic Malignancies Approval Notifications. FDA.
- Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–97.
- Baruch EN, Youngster I, Ben-Betzalel G, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021;371:602–609.
- Davar D, Dzutsev AK, McCulloch JA, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371:595–602.
- Shimizu T, Ohkuma R, Homma M, et al. Tumor Akkermansia muciniphila predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression. Frontiers in Immunology. 2025.
- Marcos-Kovandzic L, et al. Gut Microbiota Modulation through Akkermansia spp. Supplementation Increases CAR T-cell Potency. Cancer Discovery. 2025;15:1905–1926.
- Yang Z, Liang L, Li X, et al. Akkermansia muciniphila enhances the antitumour efficacy of αPD-1 therapy in gastric cancer by remodelling the tumour immune microenvironment. Toxicology and Applied Pharmacology. 2026.
- Huang L, Rong Y, Guo M, et al. Engineered Akkermansia muciniphila vesicles for targeted pyroptosis and trained immunity to enhance immunotherapy in hepatocellular carcinoma. Cell Reports Medicine. 2026.
- Lord SR, Harris AL. Is it still worth pursuing the repurposing of metformin as a cancer therapeutic? British Journal of Cancer.
- OneDayMD. Repurposed Drugs and Immunotherapy. 2025; updated 2026.
- OneDayMD. Combining Repurposed Drugs with New Immunotherapies: CAR-T and Checkpoint Inhibitors. January 2026.
- OneDayMD. Akkermansia and Cancer Immunotherapy. March 2026.
- AestheticsAdvisor Cancer. Ivermectin + Fenbendazole + Tagrisso in Stage IV NSCLC. May 2026.
- Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–97.
- Baruch EN, Youngster I, Ben-Betzalel G, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021;371:602–609.
- Davar D, Dzutsev AK, McCulloch JA, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021;371:595–602.
- Elkrief A, Routy B. First clinical proof-of-concept that FMT can overcome resistance to ICIs. Nature Reviews Clinical Oncology. 2021;18:325–326.
- Almonte AA, et al. Gut dysbiosis in oncology: a risk factor for immunoresistance. Cell Research. 2026.
- Wei D, et al. Microbiota and cancer immunotherapy: Mechanisms, clinical implications, and precision therapeutics. Seminars in Cancer Biology. 2026.
- Impact of microbiome-modulating strategies in cancer patients receiving immunotherapy (MSIT): a systematic review and meta-analysis. 2026.
- Ciappina G, et al. A Silent Saboteur of Immunotherapy: Antibiotic Use and Its Impact on Immune Checkpoint Inhibitors Efficacy. Cancers. 2026.
- Aliazis K, Christofides A, Shah R, et al. The tumor microenvironment's role in the response to immune checkpoint blockade. Nature Cancer. 2025;6:924–937.
- Hu K, et al. The Gut Microbiome Drives Endogenous T Cell Activation Following CAR-T Cell Therapy. Cancer Immunology Research. 2026.
- Gut Microbiota Modulation through Akkermansia spp. Supplementation Increases CAR T-cell Potency. 2025.
- Lord SR, Harris AL. Is it still worth pursuing the repurposing of metformin as a cancer therapeutic? British Journal of Cancer. 2023;128:958–966.
- Yuan Y, et al. A phase I/II study evaluating the safety and efficacy of ivermectin in combination with balstilimab in patients with metastatic triple negative breast cancer. Journal of Clinical Oncology. 2025;43(16_suppl):e13146.
- ClinicalTrials.gov. NCT05318469: Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer.
- OneDayMD Editorial Team. Repurposed Drugs and Immunotherapy. 2025/2026.
- OneDayMD Editorial Team. Combining Repurposed Drugs with New Immunotherapies: CAR-T and Checkpoint Inhibitors. January 2026.
- OneDayMD Editorial Team. Akkermansia and Cancer Immunotherapy: The Gut Microbe That Predicts Treatment Response. March 2026.
Unlocking therapeutic potential: integration of drug repurposing and immunotherapy in cancer – PMC
Repurposing drugs for solid tumor treatment: focus on immune modulation – PMC
Repurposable Drugs for Immunotherapy and Strategies to Find Them – MDPI
Advancements, approaches, and obstacles in repurposing drugs for cancer – Nature
Drug functional remapping: a new promise for tumor immunotherapy – Frontiers in Oncology
Drugs repurposed to potentiate immunotherapy for cancer treatment – ClinicalPub
Repurposing non-oncology small-molecule drugs to improve cancer immunotherapy – ScienceDirect
Beyond Fenbendazole and Ivermectin: Why We Need Better Conversations About Off‑Label Cancer Treatments - Jane McLelland
- This article is an evidence review and is not individualized medical advice.
- The inclusion of a drug, supplement, bacterium, dietary intervention or experimental combination does not constitute a recommendation for cancer treatment.
- Established targeted therapies, immunotherapies, chemotherapy, radiation, surgery and other evidence-based treatments should not be discontinued or replaced with experimental repurposed drugs or microbiome interventions.
- Case reports and patient stories are hypothesis-generating and cannot establish treatment efficacy.
- Cancer treatment decisions should be made with an appropriately qualified oncology team, taking into account tumor type, stage, molecular biomarkers, previous treatment, comorbidities, drug interactions and individual risk.
- This article distinguishes mechanistic, preclinical, observational, early clinical and randomized evidence. Mention of a drug, bacterium, dietary strategy or combination does not constitute a recommendation for cancer treatment.
- Patients should not discontinue chemotherapy, immunotherapy, radiation, surgery, targeted therapy or another evidence-based cancer treatment in favor of repurposed drugs, supplements, probiotics or microbiome interventions.
 |
| Diverse cancer hallmarks targeted by repurposed non-oncology drugs. This figure was created with Biorender.com. Source: Nature 2024 |
.png)
Comments
Post a Comment